Hepatitis C

Clinical Trials·Hepatitis C·News·Pharmaceuticals

Atea Pharmaceuticals Rises After Hepatitis C Data; 2026 Readouts Eyed

Atea Pharmaceuticals shares rose 1.5% to $4.60 Wednesday after reporting Phase 1 data showing its bemnifosbuvir/ruzasvir hepatitis C combo has low risk for drug-drug interactions. The company expects key Phase 3 trial results in mid-2026 and around year-end. Biotech stocks broadly traded higher. Atea’s market cap stood near $364 million.

May 27, 2026

Lloyds Banking Group Stock Trades Near 10% Discount Amid Valuation Debate
May 27, 2026, 4:35 PM EDT. Lloyds Banking Group (LSE: LLOY) shares trade at around a 10% discount to a £1.13 fair value estimate despite a recent 1.91% daily gain and 5.40% weekly rise. The bank's 1-year total shareholder return is 34.57% and 5-year return is 159.74%, highlighting strong long-term performance. Analysts cite operational leverage, AI investments, and growth in fee-generating businesses as potential margin drivers. However, the stock's price-to-earnings ratio of 12.8x exceeds peer and sector averages, raising concerns of overvaluation. Downside risks include UK economic slowdown, credit losses, and fintech competition. Investors face mixed signals between valuation discount and premium earnings multiple as they weigh Lloyds' growth prospects and macroeconomic challenges.